A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Clinical Cancer Research|2019Cited by 52
Association between radiological parameters and clinical and molecular characteristics in human somatotropinomasMaría Rosa Alhambra-Expósito, Raúl M. Luque, Alejandro Ibáñez‐Costa et al.|Scientific Reports|2018Cited by 28
Supplementary Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0
Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0
Figure S2 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0